News

The findings suggest that intensive lowering of blood pressure may reduce the risk of mild cognitive impairment and the combined risk of mild cognitive impairment and dementia, but not dementia alone.

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health discussed his thoughts about patients with mild dementia and prodromal Alzheimer disease.

The increased risk of hemorrhage was not revealed in 5-mg and 10-mg doses, implying a dose-dependent effect for rivaroxaban.

Paramedics were called to a campus party after a 911 call was placed with a report that a 19-year-old male suddenly “passed out.”

Data back a 4-fold higher dose of crenezumab in the CREAD 1 and CREAD 2 trials than used in phase II.

Midazolam is expected to receive a decision from the FDA in early 2019. If approved, it would become the first new medication for this indication in more than 15 years.

The Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program discussed the landscape of care in Alzheimer symptom management.

Hampel looks to the future of the Alzheimer space and sees promise, especially since there’s transfertilization from other advanced science fields in medicine like oncology, diabetes research and rheumatology.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about the difficulties of treating sleepiness and what solriamfetol brings to the table.

Davangere P. Devanand, MBBS, MD, discussed the possibility of neurologists prescribing low-dose lithium for patients with Alzheimer and symptoms of agitation.

The Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program discussed the ongoing study, which is exploring s-citalopram in patients with Alzheimer who also have symptoms of agitation.

Study results suggest that agonist stimulation of PPAR delta may be an effective therapeutic strategy to addressing dysfunctional metabolism in Alzheimer disease.

The approval is a first of its kind for the rare disease, and the first in a new class of drugs—small interfering ribonucleic acid (siRNA) treatments.

Findings from STROKE 2018 revealed sICH was more likely with right hemispheric patients post-alteplase infusion.

Haeberlein spoke about a number of topics in the Alzheimer space, including the progress that has been made and her excitement for the future.

Stephen D. Silberstein, MD, discussed the powerful impact that the new class of CGRP inhibitors is beginning to have on migraine.

The 2 anti-Aβ monoclonal antibodies, in treatment for Alzheimer disease, are currently being tested in 2 phase III trials.

The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.

Michael J. Thorpy, MBChB, spoke about solriamfetol’s success and the possibility of it treating other sleep conditions.

The use of DBS in early Parkinson could slow rest tremor progression in patients.

The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.

Higher doses of gantenerumab, a monoclonal antibody designed to bind to aggregated Aβ and remove beta plaques, will be investigated in phase III trials.

This guideline gives recommendations to improve diagnosis, health outcomes and care of individuals with prolonged disorders of consciousness.

The human recombinant monoclonal antibody is designed to increase progranulin levels to sustain neuron survival and moderate inflammation.

Hospitals participating in the Get With The Guidelines-Stroke program provided patients with more evidence-based interventions but highlighted a gap in intervening practices.

The senior lecturer in Clinical Pharmacy at Aston University talked about issues facing the medical community in treating those with dementia who have sleep problems.

The results conclude that treatment with crenezumab was associated with a consistent decrease in Aβ oligomer levels in the CSF.

The professor of age-related diseases and Dean of the University of Exeter Medical School provided insight into the safety and efficacy of pimavanserin studied in treatment for Alzheimer psychosis.